Business
Lexaria Releases Annual Letter from the CEO
KELOWNA, BC / ACCESS Newswire / January 12, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this Annual Letter from its Chief Executive ...
About this update from Lexaria Bioscience Corp.
[{"type":"text","content":"KELOWNA, BC / ACCESS Newswire / January 12, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this Annual Letter from its Chief Executive Officer ("CEO") Richard Christopher as a strategic update to all stakeholders.","length":355,"tagName":"p"},{"type":"text","content":"CEO Letter to Stakeholders","length":26,"tagName":"p"},{"type":"text","content":"Dear Fellow Stakeholders,","length":25,"tagName":"p"},{"type":"text","content":"I'm truly honored to deliver Lexaria's Annual Letter from the CEO following my first full year in the position.","length":119,"tagName":"p"},{"type":"text","content":"I'm pleased to report that, in 2025, Lexaria made significant progress in further evidencing the potential to advance oral based drug delivery within the GLP-1 sector with the use of its proprietary DehydraTECHTM ("DHT") technology. A number of human and animal studies were conducted and concluded in 2025 which produced extremely encouraging safety and tolerability, pharmacokinetic, weight loss, blood glucose, insulin, biodistribution, and blood pressure results.","length":481,"tagName":"p"},{"type":"text","content":"The key highlights, results, and achievements from 2025; as well as a glimpse into our 2026 plans, are summarized as follows:","length":125,"tagName":"p"},{"type":"text","content":"(Please note: all dates within this letter refer to calendar periods versus fiscal periods)","length":91,"tagName":"p"},{"type":"text","content":"2025 Highlights","length":15,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Our DHT technology once again this year demonstrated positive results in each and every research and development ("R&D") study reported on in 2025. These studies included: Human Pilot Study #3 (GLP-1-H24-3), Human Study #4 (GLP-1-H24-4), Human Pilot Study #5 (GLP-1-H25-5), and our rodent biodistribution study;","length":325,"tagName":"p"}]},{"val":[{"type":"text","content":"The Company completed its first Phase 1b registrational study (Human Study #4) in Australia;","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"10 additional patents were issued in 2025, including important new patents in the GLP-1 sector, increasing th...